Does Contineum Therapeutics, Inc. Class A Common Stock pass AAOIFI screening?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (CTNM: 1.9%), (3) interest-bearing deposits below 30% (CTNM: 59.3%), and (4) prohibited income below 5% (CTNM: 9.2%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Contineum Therapeutics, Inc. Class A Common Stock stock?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a non-permissible income ratio of 9.21%. Muslim investors should purify this percentage of any dividends received and capital gains realized from CTNM shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Contineum Therapeutics, Inc. Class A Common Stock for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about CTNM's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Contineum Therapeutics, Inc. Class A Common Stock (CTNM) halal? Not Halal. Based on AAOIFI screening, Contineum Therapeutics, Inc. Class A Common Stock passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

CTNM: Is Contineum Therapeutics, Inc. Class A Common Stock Halal?

Not Halal

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQHealthcareUS

$11.86

+4.96%

AvoidBorderlineClean

About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery and advancement of innovative oral small molecule therapies. Their primary focus lies in addressing neurological, inflammatory, and immunological disorders characterized by significant unmet medical needs. The company's foremost therapeutic candidate is PIPE-791, a pioneering, brain-penetrant small molecule designed to inhibit the lysophosphatidic acid 1 receptor (LPA1R). This compound is currently being investigated for its potential in treating idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Additionally, Contineum is developing PIPE-307, a novel small molecule functioning as a selective inhibitor of the muscarinic type 1 M1 receptor, intended for the management of depression and relapse-remitting MS. Another asset in their pipeline is CTX-343, an LPA1R antagonist with activity restricted to the periphery. Founded in 2009, this San Diego, California-headquartered organization was formerly known as Pipeline Therapeutics, Inc. before officially changing its name to Contineum Therapeutics, Inc. in November 2023.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 12, 2026

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap1.9% / 30.0%

Compliance History

Not Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 12, 2026Fiscal: FY 2024Source: FMP

Financial Overview

Market Cap

443.4M

Price

$11.86

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track CTNM and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Contineum Therapeutics, Inc. Class A Common Stock (CTNM) halal to invest in?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Contineum Therapeutics, Inc. Class A Common Stock get a F compliance rating?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.9% (limit 30%); interest-bearing deposits of 59.3% (limit 30%); prohibited income of 9.21% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Contineum Therapeutics, Inc. Class A Common Stock's Shariah verdict?

Contineum Therapeutics, Inc. Class A Common Stock's verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Contineum Therapeutics, Inc. Class A Common Stock re-screened for Shariah compliance?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 12, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.